GRI Bio Inc Sustainability Reports
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses. Its pipeline includes immune-modulating therapeutics designed to treat inflammatory, fibrotic, and autoimmune disorders.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
2 reports from 2023 to 2024
Company Profile
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses. Its pipeline includes immune-modulating therapeutics designed to treat inflammatory, fibrotic, and autoimmune disorders.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
